Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 Aug 4;222(8):e20241174.
doi: 10.1084/jem.20241174. Epub 2025 May 20.

A multimorphic variant in ThPOK causes an inborn error of immunity with T cell defects and fibrosis

Affiliations
Case Reports

A multimorphic variant in ThPOK causes an inborn error of immunity with T cell defects and fibrosis

Maryam Vaseghi-Shanjani et al. J Exp Med. .

Abstract

ThPOK is a transcription factor that acts as a master regulator of CD4+ T cell lineage commitment. We report the first human disease caused by a genetic alteration in ThPOK, specifically, a damaging heterozygous de novo variant in ThPOK (NM_001256455.2:c.1080A>C, p.K360N). This patient exhibited the unusual constellation of persistent CD4+ T cell deficiency, allergy, interstitial lung disease, corneal vascularization and scarring, developmental delay, and growth failure. The ThPOKK360N variant displayed abnormal multimorphic activity, interfering with ThPOKWT (antimorph), failing to bind wild-type ThPOK consensus sequences (amorph), and showing novel DNA-binding specificity (neomorph). Single-cell RNA sequencing revealed defects in CD4+ and CD8+ T cell maturation and activation (hypomorph). Recapitulated in lentivirally transduced healthy control T cells and fibroblasts, the transcriptomic analysis showed ThPOKK360N-transduced T cells had impaired TCR activation and ThPOKK360N-transduced fibroblasts with increased profibrotic gene expression. This novel human disease confirms ThPOK's role in CD4+ T cell development but also uncovers novel roles in TCR activation and regulation of fibrotic pathways in fibroblasts.

PubMed Disclaimer

Conflict of interest statement

Disclosures: J.H. Rayment reported personal fees from Vertex Pharmaceuticals, personal fees from Boehringer Ingelheim, and grants from Vertex Pharmaceuticals outside the submitted work. No other disclosures were reported.

Similar articles

Cited by

References

    1. Aimo, A., Spitaleri G., Nieri D., Tavanti L.M., Meschi C., Panichella G., Lupón J., Pistelli F., Carrozzi L., Bayes-Genis A., and Emdin M.. 2022. Pirfenidone for idiopathic pulmonary fibrosis and beyond. Card. Fail. Rev. 8:e12. 10.15420/cfr.2021.30 - DOI - PMC - PubMed
    1. Alsafadi, H.N., Staab-Weijnitz C.A., Lehmann M., Lindner M., Peschel B., Königshoff M., and Wagner D.E.. 2017. An ex vivo model to induce early fibrosis-like changes in human precision-cut lung slices. Am. J. Physiol. Lung Cell. Mol. Physiol. 312:L896–L902. 10.1152/ajplung.00084.2017 - DOI - PubMed
    1. Bonner, J.C. 2010. Mesenchymal cell survival in airway and interstitial pulmonary fibrosis. Fibrogenesis Tissue Repair. 3:15. 10.1186/1755-1536-3-15 - DOI - PMC - PubMed
    1. Carpenter, A.C., Grainger J.R., Xiong Y., Kanno Y., Chu H.H., Wang L., Naik S., dos Santos L., Wei L., Jenkins M.K., et al. 2012. The transcription factors Thpok and LRF are necessary and partly redundant for T helper cell differentiation. Immunity. 37:622–633. 10.1016/j.immuni.2012.06.019 - DOI - PMC - PubMed
    1. Casanova, J.-L., Conley M.E., Seligman S.J., Abel L., and Notarangelo L.D.. 2014. Guidelines for genetic studies in single patients: Lessons from primary immunodeficiencies. J. Exp. Med. 211:2137–2149. 10.1084/jem.20140520 - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources